A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antroquinonol (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions
Sponsors Golden Biotechnology Corporation

Most Recent Events

22 Feb 2024 Planned End Date changed from 30 Dec 2023 to 31 Mar 2024.
20 Jan 2024 Results (n=55) assessing dose and efficacy of antroquinonol combined with gemcitabine and nab-paclitaxel (Gem/Nab-P) on mPC patients presented at the 2024 Gastrointestinal Cancers Symposium
18 Jan 2024 Results presented in the Golden Biotechnology Corporation Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight